Neurocrine Biosciences, Inc. (NBIX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
NBIX Revenue Growth
Revenue Breakdown (FY 2025)
NBIX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
NBIX Revenue Analysis (2014–2025)
As of May 8, 2026, Neurocrine Biosciences, Inc. (NBIX) generated trailing twelve-month (TTM) revenue of $3.10 billion, reflecting explosive growth of +42.2% year-over-year. The most recent quarter (Q1 2026) recorded $814.5 million in revenue, up 1.1% sequentially.
Looking at the longer-term picture, NBIX's 5-year compound annual growth rate (CAGR) stands at +22.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $2.86 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows NBIX's business is primarily driven by Product (99%), and Collaboration Revenue (1%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including INVA (+13.6% YoY), ACAD (+9.9% YoY), and PTCT (-53.3% YoY), NBIX has outperformed the peer group in terms of revenue growth. Compare NBIX vs INVA →
NBIX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NBIXCurrent | $3.1B | +42.2% | +22.3% | 21.6% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% |
NBIX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.86B | +21.4% | $2.81B | 98.2% | $619.1M | 21.6% |
| 2024 | $2.36B | +24.8% | $2.32B | 98.6% | $570.5M | 24.2% |
| 2023 | $1.89B | +26.8% | $1.85B | 97.9% | $250.9M | 13.3% |
| 2022 | $1.49B | +31.3% | $1.47B | 98.4% | $249.0M | 16.7% |
| 2021 | $1.13B | +8.4% | $1.12B | 98.7% | $102.5M | 9.0% |
| 2020 | $1.05B | +32.7% | $1.04B | 99.0% | $163.0M | 15.6% |
| 2019 | $788.1M | +74.7% | $780.7M | 99.1% | $72.3M | 9.2% |
| 2018 | $451.2M | +179.2% | $446.3M | 98.9% | $36.8M | 8.2% |
| 2017 | $161.6M | +977.5% | $160.4M | 99.2% | $-131,361,000 | -81.3% |
| 2016 | $15.0M | -24.1% | $15.0M | 100.0% | $-147,372,000 | -982.5% |
Full NBIX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See NBIX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NBIX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NBIX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNBIX — Frequently Asked Questions
Quick answers to the most common questions about buying NBIX stock.
Is NBIX's revenue growth accelerating or slowing?
NBIX revenue is accelerating at +42.2% year-over-year, exceeding the 5-year CAGR of +22.3%. TTM revenue reached $3.1B. Growth momentum has increased versus prior periods.
What is NBIX's long-term revenue growth rate?
Neurocrine Biosciences, Inc.'s 5-year revenue CAGR of +22.3% reflects the sustained expansion pattern. Current YoY growth of +42.2% is above this long-term average.
How is NBIX's revenue distributed by segment?
NBIX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.